NCT02152995View on ClinicalTrials.gov

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 14, 2014

Primary Completion Date

August 25, 2021

Study Completion Date

January 25, 2026

Conditions
Metastatic Thyroid Gland CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaStage IV Thyroid Gland Follicular Carcinoma AJCC v7Stage IV Thyroid Gland Papillary Carcinoma AJCC v7Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
Interventions
PROCEDURE

Computed Tomography

Undergo iodine I-124 PET/CT

OTHER

Iodine I 124

Undergo iodine I-124 PET/CT

RADIATION

Iodine I-131

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacodynamic Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo iodine I-124 PET/CT

DRUG

Trametinib

Given PO

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH